Rilpivirine
Links shared publicly online about this topic
Rilpivirine (Edurant) - The Body
thebody.com — “What Is Rilpivirine? Rilpivirine is a drug used as part of antiretroviral therapy (ART). It is also called Edurant. It is manufactured by Tibotec ...” View full resource at thebody.com
Most Recently Shared on May 25, 2011 at 10:01 pm By:
New fact sheet on Edurant (rilpivirine), the latest HIV drug approved by the FDA: http://bit.ly/lxavFs #hiv #aids #nnrtis
An Overview of Edurant (Rilpivirine) - The Body
thebody.com — “Brand Name: EdurantOther Name(s): TMC278, R278474, Rilpivirine hydrochlorideDrug Class: Non-nucleoside Reverse Transcriptase Inhibitors Rilpivirine, also ...” View full resource at thebody.com
Most Recently Shared on May 26, 2011 at 3:01 pm By:
An Overview of Endurant (Rilpivirine) http://bit.ly/mNeH1r #hiv #aids #tmc278 #nnrti
Complera (Rilpivirine + Emtricitabine + Tenofovir) - The Body
thebody.com — “What Is Complera? Complera is a tablet that contains three antiretroviral drugs (ARVs) used to fight HIV: rilpivirine (Edurant), emtricitabine (Emtriva), ...” View full resource at thebody.com
Most Recently Shared on September 5, 2011 at 7:00 pm By:
Fact Sheet on Complera (Rilpivirine + Emtricitabine + Tenofovir) http://t.co/rbQiwr8 #hiv #aids #antiretrovirals #medications
FDA Approves New HIV Treatment Edurant (rilpivirine)
drugs.com — “Edurant (rilpivirine) is used to treat HIV-1 infection. Includes Edurant side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on May 21, 2011 at 1:05 am By:
FDA Approves New HIV Treatment Edurant (rilpivirine) - http://bit.ly/jlzzjz
FDA Approves New HIV Treatment Edurant (rilpivirine)
drugs.com — “Edurant (rilpivirine) is used to treat HIV-1 infection. Includes Edurant side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on May 21, 2011 at 1:04 am By:
Drugs and Devices OW OW Health
FDA Approves New HIV Treatment Edurant (rilpivirine): May 20, 2011 -- The U.S. Food and Drug Administratio... http://bit.ly/lP7KHQ #drug
An Overview of Complera (Rilpivirine/Tenofovir/Emtricitabine) - The Body
thebody.com — “ef-FAH-ver-enz / em-tri-SIT-uh-bean / te-NOE-fo-veer” View full resource at thebody.com
Most Recently Shared on August 17, 2011 at 10:01 pm By:
An Overview of Complera (Rilpivirine/Tenofovir/Emtricitabine) http://t.co/4UjBvUf #hiv #aids #antiretrovirals #medications #combination
Safety, efficacy, and pharmacokinetics of rilpivirine: systematic revi
dovepress.com — “Peer reviewed article authored by (Ford N, Lee J, Andrieux-Meyer I, Calmy A). Read article or submit your manuscript for publishing.” View full resource at dovepress.com
Most Recently Shared on April 29, 2011 at 11:26 pm By:
Drugs and Devices OW OW Health
Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited se... http://bit.ly/lRupWx
Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination
fda.gov — “FDA approval of Approval of Complera, a new emtricitabine/rilpivirine/tenofovir DFfixed dose combination product for treatment of HIV” View full resource at fda.gov
Most Recently Shared on August 11, 2011 at 3:02 pm By:
Trish D'Antonio Health Professional
HIV and AIDS Activities Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination: http://t.co/BVRnb2W
Medicine and Technology [part of HCPLive]: FDA approves Edurant (rilpivirine) for HIV
medicineandtechnology.com — “Medicine and Technology [part of HCPLive]: FDA approves Edurant (rilpivirine) for HIV” View full resource at medicineandtechnology.com
Most Recently Shared on May 20, 2011 at 6:52 pm By:
Joseph Kim, MD, MPH Doctor and Physician
FDA approves Edurant (rilpivirine) for HIV http://goo.gl/fb/UKtat
Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride
news-medical.net — “Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has signed an agreement with Tibotec Pharmaceuticals for a non-exclusive license to manufacture, market and distribute a generic version of the non-nucleoside reverse transcriptase inhibitor Rilpivirine Hydrochloride (TMC278), pending its regulatory approval for the treatment of treatment-naive HIV-1-infected adults.” View full resource at news-medical.net
Most Recently Shared on January 28, 2011 at 8:47 am By:
HIV/AIDS News: Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride: Mylan Inc. ... http://bit.ly/goRF5B
Rilpivirine Approval Offers an Alternative HIV Treatment : Skin & Allergy News
skinandallergynews.com — “Skin & Allergy News Digital Network is the online destination and multimedia properties of Skin & Allergy News, the independent news publication for the dermatology community. Our breaking news covers all areas of medical dermatology, dermatologic surgery, and aesthetic dermatology. We also provide the news by specialty interest: acne and rosacea, atopic dermatitis and eczema, cutaneous oncology, hair and nails, infectious diseases, pediatric dermatology, psoriasis and rheumatologic disorders, s” View full resource at skinandallergynews.com
Most Recently Shared on May 24, 2011 at 8:33 pm By:
Lisa Kates, M.D. Dermatologist, Physician, and Doctor
Rilpivirine Approval Offers an Alternative HIV Treatment : Skin & Allergy News http://t.co/LRR2bo4 via @AddThis
Edurant (Rilpivirine): The HIV Treatment Dating Game Just Got More Interesting - The Body
thebody.com — “Edurant (Rilpivirine): The HIV Treatment Dating Game Just Got More Interesting” View full resource at thebody.com
Most Recently Shared on May 26, 2011 at 4:15 pm By:
Edurant (Rilpivirine): The HIV Treatment Dating Game Just Got More Interesting: An Interview With Cal Cohen, M.D. http://bit.ly/jAqb1O #hiv
DHHS Adult and Adolescent Antiretroviral Treatment Guidelines Panel Releases Supplemental Information Regarding the Role of Rilpivirine as Initial Therapy - The Body
thebody.com — “Rilpivirine (RPV) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) recently approved by the Food and Drug Administration (FDA) as part of a ...” View full resource at thebody.com
Most Recently Shared on August 16, 2011 at 10:01 pm By:
Adult & Adolescent Treatment Guidelines Panel Releases Supplemental Information on Rilpivirine as Initial Therapy http://t.co/ZTvQB7d
Approval of Edurant (Rilpivirine), a New NNRTI, for the Treatment of HIV in Treatment Naive Patients - The Body
thebody.com — “On Friday, May 20, 2011, FDA approved Edurant (rilpivirine) 25 mg tablets, a new non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment ...” View full resource at thebody.com
Most Recently Shared on May 20, 2011 at 7:26 pm By:
Here's the official FDA approval notice on Edurant (rilpivirine), the first new NNRTI for HIV treatment since 2008: http://bit.ly/iHbHD1
FDA Approves EDURANT™ (rilpivirine) For Use In Treatment-Naïve Adults With HIV-1 - QualityPoint Technologies
qualitypointtech.net — “The US Food and Drug Administration (FDA) approved EDURANTTM (rilpivirine) tablets for use in combination with other antiretroviral agents (ARVs) in the treatment of human immunodeficiency virus type 1 (HIV-1) in adults who have never taken HIV therapy (treatment naïve). EDURANT (pronounced ee' dur ant) was developed as TMC278 (rilpivirine) by Tibotec Pharmaceuticals and is a non-nucleoside reverse transcriptase inhibitor, or NNRTI...” View full resource at qualitypointtech.net
Most Recently Shared on May 21, 2011 at 9:45 am By:
FDA Approves EDURANT™ (rilpivirine) For Use In Treatment-Naïve Adults With HIV-1: The US Food and Drug Admini... http://bit.ly/mpJUNZ
The Top 3 resources shared on this topic. More resources.
Advertisement
